NewsBenzingaCitizens mantiene una recomendación de rendimiento superior al mercado para Halozyme Therapeutics y eleva el precio objetivo a 149 dólares Citizens mantiene una recomendación de rendimiento superior al mercado para Halozyme Therapeutics y eleva el precio objetivo a 149 dólares Benzinga 2026.11.06 15:21 (GMT+0) Open on Benzinga Other news RBC Capital Maintains Outperform on Acadia Healthcare Co, Raises Price Target to $41 Oppenheimer Maintains Outperform on EverCommerce, Lowers Price Target to $11 RBC Capital Downgrades Brookfield Business to Sector Perform, Maintains Price Target to $34 Energy Vault Japan Collaborates With PowerX To Explore Supply Of 1.5 GWh of PowerX’s Mega Power Series For Energy Vault's U.S. Projects Next Year Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery Oppenheimer Maintains Outperform on BILL Holdings, Raises Price Target to $60
Energy Vault Japan Collaborates With PowerX To Explore Supply Of 1.5 GWh of PowerX’s Mega Power Series For Energy Vault's U.S. Projects Next Year
